Thyroid dysfunction during treatment with atypical antipsychotics [3]

Journal of Clinical Psychiatry

Volumn 66, Issue 10, 2005, Pages 1334-1335

  Greenspan, Andrew ^a   Gharabawi, Georges ^a   Kwentus, Joseph ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPHENAZINE; LIOTHYRONINE; LITHIUM; QUETIAPINE; RISPERIDONE; THYROTROPIN; THYROXINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG RESPONSE; HORMONE DETERMINATION; HUMAN; HYPOTHYROIDISM; LETTER; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 27544436999     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1019e     Document Type: Letter

References (6)

1. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005;66:80-84
2. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004;363:793-803
3. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273
4. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246
5. Small JG, Hirsch SR, Arvanitis LA, et al, and the Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
6. Greenspan A, Kosik-Gonzales C, Bossie C, et al. Readiness to discharge among inpatients with schizophrenia: effects of risperidone, quetiapine, and placebo [poster]. Presented at the Collegium Internationale Neuro- Psychopharmacologicum; June 20-24, 2004; Paris, France